NEWTOWN, Pa. — January 13, 2026 — Leads & Copy — Traws Pharma, Inc. (NASDAQ: TRAW) has announced the filing of a U.S. IND application with the U.S. Food and Drug Administration (FDA) for tivoxavir marboxil (TXM), a potential best in class CAP-dependent endonuclease inhibitor for the treatment of influenza.
The company also released updated interim clinical results from its Phase 2 COVID study of ratutrelvir, an investigational oral Mpro/3CL protease inhibitor, which confirmed a differentiated clinical profile versus PAXLOVID® with fewer adverse events, no viral rebounds and faster time to sustained symptom resolution. The study included a single arm of PAXLOVID®-ineligible subjects, with ratutrelvir demonstrating a safety and efficacy advantage in this population.
According to C. David Pauza, PhD, Chief Scientific Officer of Traws Pharma, the IND filing represents an important step toward formal consideration of TXM for influenza therapy and inclusion in the strategic national stockpile. He added that the company remains optimistic about the potential inclusion of TXM in the nation’s armamentarium against potential future disease outbreaks, in light of ongoing positive interactions with the U.S. Department of Health and Human Services (HHS) regarding the unique properties of TXM as a broad pan-influenza strain therapeutic.
The Phase 2 COVID study evaluated patient-reported symptom outcomes, safety, and real-world usability of ratutrelvir compared to PAXLOVID®. Patients in the ratutrelvir arm received 600 mg orally once daily for 10 days, while patients in the comparator arm received PAXLOVID® as nirmatrelvir 300 mg twice daily plus 100mg ritonavir twice daily for 5 days. The interim analysis included 50 patients, with 32 patients treated with ratutrelvir and 18 patients treated with PAXLOVID®. The company expects full study enrollment in January 2026.
According to Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma, the interim data confirm that ratutrelvir may provide a meaningful benefit across a broader range of patients, including those who are unable to receive ritonavir-boosted therapy. He said that the favorable tolerability profile, together with a shortened time to symptom resolution and the absence of viral rebound events in ratutrelvir-treated patients, supports the continued clinical evaluation of ratutrelvir in both acute COVID-19 and in studies designed to better understand its potential impact on longer-term outcomes.
Ratutrelvir-treated patients demonstrated time-to-sustained symptom alleviation and resolution that was numerically superior to PAXLOVID® -treated patients (12 days versus 14 days, respectively (p<0.014)). No COVID-19 symptom or virologic rebound events have been observed to date in ratutrelvir-treated patients, while one rebound event was observed in the PAXLOVID® comparator arm. Thirteen patients treated with ratutrelvir were ineligible for PAXLOVID® and demonstrated patient-reported symptom improvement dynamics and safety consistent with those observed in the broader ratutrelvir-treated cohort.
Ratutrelvir was well tolerated in the interim analysis, with fewer reported adverse events compared with the PAXLOVID®-treated cohort. Among ratutrelvir-treated patients, the most commonly reported adverse event was mild dyspepsia, reported in 2 patients (7.6%). No dysgeusia or ritonavir-associated adverse effects were reported, and no treatment discontinuations due to adverse events were observed. Adverse events commonly associated with PAXLOVID®, including dysgeusia, dizziness, and dyspepsia, were reported in 4 patients (30%) in the comparator arm.
Iain Dukes MA DPhil, Chief Executive Officer of Traws Pharma, said that the interim data position ratutrelvir as a next-generation oral 3CL protease inhibitor with ritonavir-free administration, once-daily oral dosing, an improved time to symptom resolution and tolerability profile, with applicability to PAXLOVID®-ineligible populations, and potential relevance to long-COVID prevention strategies.
Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to be a broadly acting treatment for SARS-CoV-2/COVID-19 that is used without ritonavir. Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases.
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
Source: Traws Pharma